Earnings transcript
Read the complete earnings call transcript.

| Exchange: | NYSE |
| Market Cap: | 64.269B |
| Shares Outstanding: | 1.48B |
| Sector: | HealthcareView sector performance | |||||
| Industry: | Medical – DevicesView industry performance | |||||
| CEO: | Michael F. Mahoney | |||||
| Full Time Employees: | 59000 | |||||
| Address: |
| |||||
| Website: | https://www.bostonscientific.com |
Click to read more…
Welcome back to MarketSnap. Let me start with a contradiction that's been bothering me. Boston Scientific is down almost 60% over the past year. Its medical-devices industry is roughly flat over the same stretch, and healthcare as a sector is actually up a touch. So this isn't a sector falling apart — it's one company being repriced. On Wednesday's session, the stock fell another 6% after the company cut its fourth-quarter sales and full-year earnings guidance, citing the cyberattack. It…
| TICKER | COMPANY | MKT CAP | P/E | FWD P/E | ROIC |
|---|---|---|---|---|---|
| Boston Scientific Corporation | 64.3B | 18.7 | 14.0 | 10.5% | |
| Edwards Lifesciences Corporation | 61.6B | 60.5 | 35.5 | 9.3% | |
| GE HealthCare Technologies Inc. | 37.5B | 17.5 | 16.5 | 7.8% | |
| DexCom, Inc. | 31.1B | 32.2 | 30.9 | 24.0% | |
| Koninklijke Philips N.V. | 29.5B | 27.2 | 16.6 | 6.6% | |
| Zimmer Biomet Holdings, Inc. | 19.5B | 26.0 | 12.1 | 5.3% |
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Read the complete earnings call transcript.
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Log in — it's free| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 14,240,000 | 16,747,000 | 20,074,000 |
| Gross Profit | 8,831,000 | 10,267,000 | 13,853,000 |
| EBITDA | 3,453,000 | 3,938,000 | 5,102,000 |
| Operating Income | 2,181,000 | 2,635,000 | 3,971,000 |
| Net Income | 1,593,000 | 1,854,000 | 2,886,000 |
(* All numbers are in thousands)
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 35,136,000 | 39,395,000 | 43,673,000 |
| Total Liabilities | 15,606,000 | 17,392,000 | 19,201,000 |
| Total Stockholders Equity | 19,282,000 | 21,770,000 | 24,233,000 |
| Total Debt | 9,492,000 | 11,147,000 | 11,436,000 |
| Cash and Cash Equivalents | 865,000 | 414,000 | 1,965,000 |
(* All numbers are in thousands)
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 2,503,000 | 3,435,000 | 4,534,000 |
| Capital Expenditure | -800,000 | -790,000 | -876,000 |
| Free Cash Flow | 1,703,000 | 2,645,000 | 3,658,000 |
| Net Income | 1,592,000 | 1,846,000 | 2,892,000 |
| Net Change in Cash | -82,000 | -449,000 | 1,541,000 |
(* All numbers are in thousands)
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 25,205,326.948 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 26,646,597.549 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 25,569,333.333 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 8,798,196.213 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 9,340,648.580 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 8,935,203.761 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 5,879,093.993 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 6,318,028.644 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 5,989,956.004 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 9,013,160.552 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 9,528,543.802 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 9,143,325.417 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 4.010 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 4.230 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 3.930 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 12 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 3 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in with Research Access to see up to 5 years of analyst estimates.
Create a free account(* All numbers are in thousands)
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Log in — it's freeLog in to continue
Log in with Research Access for forward P/E high/low estimates and the full multi-year table.
Create a free accountLog in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
Based on current fundamentals and analyst forecasts, MarketSnap estimates BSX intrinsic value between $53.58 – $62.93 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
MarketSnap estimates intrinsic value for Boston Scientific Corporation (BSX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether BSX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
You can see BSX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Whether BSX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot

Trading Metrics:
| Open: | 44.69 | Previous Close: | 44.2 | |
| Day Low: | 44.08 | Day High: | 44.69 | |
| Year Low: | 39.57 | Year High: | 104.62 | |
| Price Avg 50: | 44.06 | Price Avg 200: | 54.38 | |
| Volume: | 9.697M | Average Volume: | 19.563M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Log in — it's freeUses MarketSnap data and this page
The AI-powered workspace for stock pickers.
Continue with Google Continue with emailAlready a member? Sign in
Find stocks·Value them·Build the case·Journal decisions·Track what changes
Free to join. No card needed. Privacy Policy